康诺亚生物医药科技(成都)有限公司 Mediaroom

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announce...

2025-08-27 14:02 998

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced...

2025-06-13 17:02 1389

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or t...

2025-04-25 17:44 1988

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

CHENGDU, China, April 24, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or t...

2025-04-25 11:37 2230

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or th...

2025-04-06 10:12 3276

Keymed Biosciences Announces Annual Results of 2024

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 0216...

2025-03-26 23:09 2935

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the N...

2025-02-08 09:14 4979

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced...

2024-12-23 22:31 2640

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

CHENGDU, China, Sept.12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced...

2024-09-13 00:07 2537

Keymed Biosciences Announces Interim Results for First Half of 2024

CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announce...

2024-08-27 21:10 2817

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced...

2024-06-20 14:51 2019

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced ...

2024-06-03 09:14 2095

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-...

2024-03-27 01:16 1862

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its ...

2023-03-18 08:00 6023

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 0216...

2023-02-23 13:01 2366

Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM

CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is ple...

2023-01-18 09:52 2311

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the C...

2022-09-22 13:05 1607

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that...

2022-06-10 18:42 2480

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S....

2022-04-20 10:27 1958

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States

CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new ...

2022-04-12 15:45 1042

Latest News